Birth defects in relation to Bendectin use in pregnancy. II. Pyloric stenosis.
To test the hypothesis that the use of Bendectin in pregnancy increases the risk of pyloric stenosis, we determined rates of antenatal Bendectin exposure among 325 infants with pyloric stenosis and among two control groups comprising infants with other defects; one consisted of 3,153 infants with other conditions, and the other, a subset of that group, consisted of 724 infants with defects that may have had their origins at any time in pregnancy. Comparisons between the cases and the two control series yielded estimated relative risks of 0.9 (95% confidence interval, 0.6 to 1.2) and 1.0 (0.7 to 1.4), respectively. The findings from this large case-control study suggest that Bendectin does not increase the risk of pyloric stenosis.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D004025:Dicyclomine; D004319:Doxylamine / Q000009:adverse effects*; D004338:Drug Combinations / Q000009:adverse effects; D005260:Female; D006801:Humans; D006939:Hyperemesis Gravidarum / Q000188:drug therapy; D007223:Infant; D008297:Male; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011295:Prenatal Care; D011707:Pyloric Stenosis / Q000139:chemically induced* / Q000235:genetics; D011725:Pyridines / Q000009:adverse effects*; D011736:Pyridoxine / Q000009:adverse effects*; D012306:Risk; D012737:Sex Factors; D011795:Surveys and Questionnaires
D004338:Drug Combinations; D011725:Pyridines; C004454:dicyclomine, doxylamine, pyridoxine drug combination; D004025:Dicyclomine; D004319:Doxylamine; D011736:Pyridoxine